Company intelligence / Profile preview
JKT Biopharma Co., Ltd.
Not specified, Hubei Sheng, Chinabiofarma.co.id ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
JKT Biopharma is a private Chinese biotech company founded in 2022, focused on developing small molecule therapeutics for infectious and respiratory diseases. Its lead asset, SHEN-211—a SARS-CoV-2 3CLpro inhibitor targeting COVID‑19—is in Phase 2 clinical trials as of early 2025. No approved products or published clinical results are available yet.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Small molecules (specifically chemical drugs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on JKT Biopharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JKT Biopharma Co., Ltd..